Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Audit Opinion:
Clean - Limited review conducted by S.R. Batliboi & Associates LLP with no modifications or qualifications
Key Financial Highlights [Rs. in million]:
Standalone Results:
Quarter Ended September 30, 2026:
- Revenue from Operations: ₹7,779 (Q2 FY26: ₹8,301, -6.3% YoY)
- Total Income: ₹8,054 (Q2 FY26: ₹8,443)
- Net Profit: ₹487 (Q2 FY26: ₹662, -26.4% YoY)
- EPS: ₹1.21 (Q2 FY26: ₹1.65)
Half Year Ended September 30, 2026:
- Revenue from Operations: ₹14,409 (H1 FY26: ₹16,294, -11.6% YoY)
- Total Income: ₹14,932 (H1 FY26: ₹16,602)
- Net Profit: ₹466 (H1 FY26: ₹1,402, -66.8% YoY)
- EPS: ₹1.16 (H1 FY26: ₹3.49)
Consolidated Results:
Quarter Ended September 30, 2026:
- Revenue from Operations: ₹8,327 (Q2 FY26: ₹9,106, -8.5% YoY)
- Total Income: ₹8,607 (Q2 FY26: ₹9,260)
- Net Profit: ₹322 (Q2 FY26: ₹671, -52.0% YoY)
- EPS: ₹0.80 (Q2 FY26: ₹1.67)
Half Year Ended September 30, 2026:
- Revenue from Operations: ₹15,687 (H1 FY26: ₹17,851, -12.1% YoY)
- Total Income: ₹16,220 (H1 FY26: ₹18,182)
- Net Profit: ₹232 (H1 FY26: ₹1,538, -84.9% YoY)
- EPS: ₹0.58 (H1 FY26: ₹3.82)
Other Equity:
- Consolidated: ₹44,551 million (March 2026: ₹44,362 million)
- Standalone: ₹43,271 million (March 2026: ₹43,009 million)
Cash and Cash Equivalents:
- Consolidated: ₹1,199 million (March 2026: ₹2,286 million)
- Standalone: ₹694 million (March 2026: ₹1,205 million)
Debt:
Consolidated:
- Short-term Borrowings: ₹672 million (March 2026: ₹94 million)
- Lease Liabilities: ₹4,402 million (Current ₹209 million + Non-current ₹4,193 million)
Standalone:
- Lease Liabilities: ₹1,960 million (Current ₹109 million + Non-current ₹1,851 million)
Segment-wise Performance:
The Group operates in a single segment of providing Contract Research and Manufacturing Services
Corporate Actions:
- Dividend: Paid ₹505 million during H1 FY27 (same as H1 FY26)
- ESOP: On April 29, 2026, allotted 729,727 equity shares to Syngene Employees Welfare Trust at face value for Long Term Incentive Plan
Other Significant Information:
Exceptional Items:
- Q2 FY27: ₹67 million termination benefits to employees
- Q1 FY26: ₹135 million termination benefits
- FY26: ₹303 million termination benefits and ₹732 million labour code impact
Capital Work in Progress:
- Consolidated: ₹11,406 million (including US biologics site acquisition of ₹4,876 million)
- Standalone: ₹5,558 million
US Acquisition:
Syngene USA Inc. acquired biologics site in USA from Emergent Manufacturing Operations Baltimore, LLC during Q4 FY25, accounted as asset acquisition